CONNECT WITH US
eCommerce

eCommerce

Galderma to Acquire ZO Skin Health for $1.5 Billion

WWD logo

Published on

Add as a preferred source on Google
Galderma to Acquire ZO Skin Health for $1.5 Billion

PARIS – Galderma is delving deeper into the dermatological skin care category as it agrees to acquire ZO Skin Health for $1.5 billion from its shareholders that include funds managed by Blackstone through its Tactical Opportunities segment and the Obagi family.

The acquisition of 100 percent of ZO Skin Health will be made in an all-cash transaction and funded through cash reserves and bank financing. The deal is expected to close in the fourth quarter of this year or in early 2027.

ZO Skin Health, founded by dermatologist Dr. Zein Obagi, is a leading physician-dispensed skin care brand founded on clinical science and protocol-based daily care. It is based in Irvine, Calif.

ZO Skin Health’s portfolio includes more than 40 products, which are sold through a network of over 16,500 physicians, medical spas and online accounts in more than 40 countries.

In the 12 months to June, ZO Skin Health posted net sales of about $330 million.

“This acquisition is another important step towards building the world’s most innovative dermatology portfolio, strengthening our offering in an area where we already have significant capabilities,” said Flemming Ornoskov, chief executive officer of Galderma, in a statement. “ZO Skin Health brings strong clinical credentials, a distinctive protocol-based approach and a trusted position among dermatologists and plastic surgeons.

“We see significant opportunities to reignite its growth through investment in innovation and commercial reach,” he continued.



Source link
Related Topics:eCommerce

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.